Stay updated on Telisotuzumab vs Docetaxel in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page

  1. Check
    9 days ago
    Change Detected
    Summary
    Added Jeroen Bosch Ziekenhuis as a recruitment site in 's-Hertogenbosch, Netherlands (ID 234087); total locations updated to 315.
    Difference
    0.1%
    Check dated 2026-03-08T01:39:36.000Z thumbnail image
  2. Check
    16 days ago
    No Change Detected
  3. Check
    31 days ago
    Change Detected
    Summary
    The page revision was updated from v3.4.1 to v3.4.2.
    Difference
    0.0%
    Check dated 2026-02-14T11:13:20.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    Revision: v3.4.1 was added and Revision: v3.4.0 was removed, indicating a minor update to the site. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-07T06:58:23.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    Glossary display added. The study description now includes Telisotuzumab Vedotin dosing, 1:1 randomization with docetaxel, enrollment of about 698 participants across ~330 sites, and expanded lists of investigators and locations.
    Difference
    0.8%
    Check dated 2026-01-24T05:34:05.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    Revision: v3.3.4 updated on the Study Details page, replacing v3.3.3. The update appears to be a minor revision with no changes to study details, eligibility criteria, or outcomes.
    Difference
    0.0%
    Check dated 2026-01-17T04:11:40.000Z thumbnail image
  7. Check
    88 days ago
    Change Detected
    Summary
    Expanded the Study Details by adding a comprehensive list of enrollment sites across the United States and multiple countries and removed the HHS Vulnerability Disclosure section.
    Difference
    4%
    Check dated 2025-12-19T12:15:06.000Z thumbnail image

Stay in the know with updates to Telisotuzumab vs Docetaxel in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.